ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Aurinia reports favourable assessment of LUPKYNIS in ICER pharmaceutical-technology
March 18, 2021Aurinia Pharmaceuticals (IPHAF) has announced a positive cost-effectiveness assessment of LUPKYNIS (voclosporin) based on the Institute for Clinical and Economic Review (ICER) revised evidence report analysis.
Pharma Sources Insight July 2025
